Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25012254 | 0.88 | CRBN (0.56) | CRBNDDB1TNFIKZF2 | |
| SCHEMBL30270743 | 0.88 | CRBN (0.56) | CRBNDDB1TNFIKZF2 | |
| SCHEMBL26184312 | 0.88 | CRBN (0.56) | CRBNDDB1TNFIKZF2 | |
| SCHEMBL25650358 | 0.85 | CRBN (0.54) | CRBNTNFIKZF2 | |
| SCHEMBL25010116 | 0.85 | CRBN (0.54) | CRBNDDB1TNFIKZF2 | |
| SCHEMBL23066004 | 0.85 | CRBN (0.54) | CRBNTNFIKZF2 | |
| SCHEMBL25010168 | 0.85 | CRBN (0.54) | CRBNDDB1IKZF2 | |
| SCHEMBL25229563 | 0.85 | CRBN (0.51) | CRBNDDB1TNFIKZF2 | |
| SCHEMBL25010291 | 0.85 | CRBN (0.51) | CRBNDDB1TNFIKZF2 | |
| SCHEMBL25011286 | 0.84 | CRBN (0.53) | CRBNIKZF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612140-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | Captor Therapeutics S.A. (PL) | 2025-09-10 | — | — | EP | disclosed |
| WO-2025085416-A1 | GSPT1 COMPOUNDS AND METHODS OF USE OF THE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025085489-A1 | GSPT1-DEGRADING COMPOUNDS, ANTI-CD33 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2024096753-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024096753-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024094819-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024094819-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2024-05-10 | — | — | WO | disclosed |
| EP-4323352-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| CN-117279910-A | Modulators of BCL6 proteolysis and related methods of use | 阿尔维纳斯运营股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-116239566-A | E3 ubiquitin ligase ligand compound, protein degradation agent developed based on ligand compound and application thereof | 标新生物医药科技(上海)有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20230045737-A1 | SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEO-SUBSTRATE RECRUITMENT | VIVIDION THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230045737-A1 | SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEO-SUBSTRATE RECRUITMENT | VIVIDION THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2022266258-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 | ARVINAS OPERATIONS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022266258-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 | ARVINAS OPERATIONS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | CRBN 4/4885DDB1 263/4885TNF 3554/4885 |
| US-20230045737-A1 | SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEO-SUBSTRATE RECRUITMENT | CRBN, CLNS1A, CDR2 | CRBN 1/4885DDB1 1070/4885TNF 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.